论文部分内容阅读
目的探讨辛伐他汀治疗慢性心力衰竭患者并观察其对血清脂联素和可溶性细胞间粘附分子(sICAM-1)的影响。方法 2008年6月-2010年12月在我院收治住院的80例慢性心力衰竭患者。随机分为两组,常规治疗组和干预组,每组40例。常规治疗组男26例,女14例,平均年龄为(53.7±12.3)岁,干预组男30例,女10例,平均年龄为(54.5±13.2)岁,在常规治疗的基础上加用辛伐他汀,每天10 mg,晚上8时服用,治疗4周。采用酶联免疫法(双抗体夹心)检测两组患者治疗前后血清脂联素和sICAM-1水平。结果治疗前心功能Ⅳ级患者sICAM-1水平明显高于心功能III、II级患者(P<0.05),而血清脂联素低于心功能Ⅱ、Ⅲ级患者(P<0.05),心功能III、II级之间比较差异无统计学意义(P>0.05);治疗后两组患者血清脂联素升高水平和sICAM-1下降水平均较治疗前差异有统计学意义(P<0.05),干预组较常规治疗组血清脂联素升高水平和sICAM-1下降水平差异有统计学意义(P<0.05)。结论辛伐他汀可明显增加慢性心力衰竭患者血清脂联素水平和降低sICAM-1水平,有利于抑制炎症反应。
Objective To investigate the effects of simvastatin on patients with chronic heart failure and its effects on serum adiponectin and soluble intercellular adhesion molecule (sICAM-1). Methods From June 2008 to December 2010, 80 patients with chronic heart failure admitted to our hospital were enrolled. Randomly divided into two groups, conventional treatment group and intervention group, 40 cases in each group. In the conventional treatment group, there were 26 males and 14 females, with an average age of (53.7 ± 12.3) years. The intervention group consisted of 30 males and 10 females, with an average age of (54.5 ± 13.2) years. On the basis of routine treatment, Statin, 10 mg daily, taken at 8 pm for 4 weeks. Serum levels of adiponectin and sICAM-1 were measured by enzyme-linked immunosorbent assay (double antibody sandwich) before and after treatment. Results Before treatment, the level of sICAM-1 in patients with grade IV heart function was significantly higher than those in patients with grade III and II cardiac function (P <0.05), while the level of serum adiponectin was lower in patients with grade II and III heart function (P <0.05) There was no significant difference between the two groups (P> 0.05). The levels of serum adiponectin and sICAM-1 in the two groups after treatment were significantly lower than those before treatment (P <0.05) (P <0.05). The serum adiponectin level and sICAM-1 level in the intervention group were significantly lower than those in the conventional treatment group (P <0.05). Conclusion Simvastatin can significantly increase the level of serum adiponectin and reduce the level of sICAM-1 in patients with chronic heart failure, which is beneficial to suppress the inflammatory reaction.